Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Shionogi Sees Sales Dip in Q1 despite Japan Growth; Crestor Royalty Nearly Zero
August 3, 2021
- Chugai Launches Blood-Based Comprehensive Genomic Profiling Test for Solid Tumors
August 3, 2021
- AstraZeneca to Start e-Labeling, Will Complete Process for All Products by 2022-End
August 3, 2021
- Viatris Takes Over Celecox, Lipitor MAs in Japan
August 3, 2021
- MSD Renews Warning for Fainting after Gardasil Vaccination
August 3, 2021
- Takeda to Challenge Irish Authorities’ Break Fee Tax Assessment
August 3, 2021
- Kowa Recalls All Lots of Livalo OD Tablets 1 mg over Purity Test Results
August 3, 2021
- Astellas Hooks Up with Israeli Firm for Mitochondrial Cell Therapy Programs
August 3, 2021
- Ono Chief, Honjo to Face Off in Opdivo Royalty Feud on September 2
August 3, 2021
- Daiichi Sankyo’s Q1 Sales Surge on Upbeat Global Brands
August 2, 2021
- Astellas Logs Sales Growth in Q1, but Profits Drop Sharply on Write-Offs
August 2, 2021
- Takeda’s Q1 Sales Rise on Diabetes Divestiture; Plant Re-Inspection Results Expected Late October
August 2, 2021
- PeptiDream, Alnylam Collaborate to Discover and Develop Peptide-siRNA Conjugates
August 2, 2021
- Biogen, Eisai Reveal Real-World Study Design of Aducanumab
August 2, 2021
- Ono’s Q1 Sales Up 16.6% on Opdivo Indication Expansions
August 2, 2021
- Nicholas Jones Named New Biogen Japan President
August 2, 2021
- Takeda, American VC Forge New Company to Develop Norovirus Vaccine
August 2, 2021
- Sumitomo Dainippon’s Q1 Sales Skid 2.0% on Lower Latuda Revenue
July 30, 2021
- Takeda’s Narcolepsy Drug Snags FDA’s Breakthrough Therapy Tag
July 30, 2021
- Tissue-Engineering Market in 5 Asian Areas to Approach 700 Billion Yen in 2030: Fuji Keizai
July 30, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…